[go: up one dir, main page]

WO2005092362A3 - Pharmaceutical combined preparation containing a therapeutic protein - Google Patents

Pharmaceutical combined preparation containing a therapeutic protein Download PDF

Info

Publication number
WO2005092362A3
WO2005092362A3 PCT/AT2005/000107 AT2005000107W WO2005092362A3 WO 2005092362 A3 WO2005092362 A3 WO 2005092362A3 AT 2005000107 W AT2005000107 W AT 2005000107W WO 2005092362 A3 WO2005092362 A3 WO 2005092362A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic protein
combined preparation
preparation containing
pharmaceutical combined
pharmaceutical
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AT2005/000107
Other languages
German (de)
French (fr)
Other versions
WO2005092362A2 (en
Inventor
Seth Hallstroem
Harald Gasser
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US10/599,401 priority Critical patent/US8518869B2/en
Priority to EP05714189A priority patent/EP1737480A2/en
Publication of WO2005092362A2 publication Critical patent/WO2005092362A2/en
Publication of WO2005092362A3 publication Critical patent/WO2005092362A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/41—Porphyrin- or corrin-ring-containing peptides
    • A61K38/42—Haemoglobins; Myoglobins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/75—Fibrinogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to a pharmaceutical combined preparation containing a therapeutic protein with SH groups that are nitrosated, and containing a compound comprising thiol groups and having an average molecular weight of no greater than 10,000.
PCT/AT2005/000107 2004-03-29 2005-03-24 Pharmaceutical combined preparation containing a therapeutic protein Ceased WO2005092362A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/599,401 US8518869B2 (en) 2004-03-29 2005-03-24 Pharmaceutical combined preparation containing a therapeutic protein
EP05714189A EP1737480A2 (en) 2004-03-29 2005-03-24 Pharmaceutical combined preparation containing a therapeutic protein

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ATA556/2004 2004-03-29
AT5562004 2004-03-29

Publications (2)

Publication Number Publication Date
WO2005092362A2 WO2005092362A2 (en) 2005-10-06
WO2005092362A3 true WO2005092362A3 (en) 2006-02-23

Family

ID=34962264

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2005/000107 Ceased WO2005092362A2 (en) 2004-03-29 2005-03-24 Pharmaceutical combined preparation containing a therapeutic protein

Country Status (3)

Country Link
US (2) US8518869B2 (en)
EP (1) EP1737480A2 (en)
WO (1) WO2005092362A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017525370A (en) 2014-08-21 2017-09-07 ザ ジェネラル ホスピタル コーポレイション Tumor necrosis factor superfamily and TNF-like ligand muteins and methods of preparing and using tumor necrosis factor superfamily and TNF-like ligand muteins
GB201506236D0 (en) * 2015-04-13 2015-05-27 Jellagen Pty Ltd Modified collagen, methods of manufacture thereof
US20160367620A1 (en) 2015-06-19 2016-12-22 Harry B. Demopoulos Glutathione
HUE055139T2 (en) 2015-08-07 2021-11-29 Alx Oncology Inc Compositions comprising the SIRP-alpha domain or a variant thereof
EA034582B1 (en) 2015-08-07 2020-02-21 АЭлЭкс ОНКОЛОДЖИ ИНК. Sirp-alpha variant constructs and use thereof
AU2020282791A1 (en) 2019-05-31 2021-12-09 ALX Oncology Inc. Methods of treating cancer with SIRP alpha Fc fusion in combination with an immune checkpoint inhibitor
CA3216908A1 (en) 2021-05-13 2022-11-17 ALX Oncology Inc. Combination therapies for treating cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0853944A2 (en) * 1997-01-17 1998-07-22 IMMUNO Aktiengesellschaft Preparation containing proteins having thiol groups
WO2001065935A1 (en) * 2000-03-08 2001-09-13 Yoram Vodovotz Kidney perfusion solution containing nitric oxide donor

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0486621A4 (en) * 1989-08-09 1993-03-31 The Children's Medical Center Corporation Nmda oxidizing agents for protecting neurons from injury
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0853944A2 (en) * 1997-01-17 1998-07-22 IMMUNO Aktiengesellschaft Preparation containing proteins having thiol groups
WO2001065935A1 (en) * 2000-03-08 2001-09-13 Yoram Vodovotz Kidney perfusion solution containing nitric oxide donor

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CRANE MICHAEL S ET AL: "Novel role for low molecular weight plasma thiols in nitric oxide-mediated control of platelet function.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 6 DEC 2002, vol. 277, no. 49, 6 December 2002 (2002-12-06), pages 46858 - 46863, XP002338092, ISSN: 0021-9258 *
MEYER D J ET AL: "Kinetics and equilibria of S-nitrosothiol-thiol exchange between glutathione, cysteine, penicillamines and serum albumin", FEBS LETTERS 1994 NETHERLANDS, vol. 345, no. 2-3, 1994, pages 177 - 180, XP002338093, ISSN: 0014-5793 *
RICHARDSON G ET AL: "Potential therapeutic uses for S-nitrosothiols.", CLINICAL SCIENCE (LONDON, ENGLAND : 1979) JAN 2002, vol. 102, no. 1, January 2002 (2002-01-01), pages 99 - 105, XP002338091, ISSN: 0143-5221 *

Also Published As

Publication number Publication date
WO2005092362A2 (en) 2005-10-06
EP1737480A2 (en) 2007-01-03
US8518869B2 (en) 2013-08-27
US20140051634A1 (en) 2014-02-20
US20070238641A1 (en) 2007-10-11

Similar Documents

Publication Publication Date Title
WO2005041924A3 (en) Administration of levodopa and carbidopa
WO2004009774A3 (en) Protein conjugates with a water-soluble biocompatible, biogradable polymer
WO2007090393A3 (en) Microtablet-based pharmaceutical preparation
WO2008015249A3 (en) Cosmetic or pharmaceutical composition containing hyaluronic acid
WO2004006858A3 (en) Compounds, compositions, and methods employing same
WO2004082634A3 (en) Facially amphiphilic polymers and oligomers and uses thereof
WO2006002840A3 (en) Aerosol suspension formulations containing tg 227 ea or tg 134 a as a propellant
WO2005074970A3 (en) Neuroprotective dietary supplement
WO2003063851A8 (en) Composition for pharmaceutical or dietetic use for combating hair loss
WO2004031352A3 (en) Interferon variants with improved properties
WO2004098536A3 (en) Anti-viral activity of cathelicidin peptides
WO2004082629A3 (en) Novel cyclosporins
WO2005032490A3 (en) Cyclic diamines and derivatives as factor xa inhibitors
WO2004039326A3 (en) Propofol with cysteine
WO2005092362A3 (en) Pharmaceutical combined preparation containing a therapeutic protein
IL181216A (en) 3, 5-seco-4-norcholestane derivatives and pharmaceutical compositions containing the same
WO2006056696A3 (en) 2-alcoxy-3,4,5-trihydroxy-alkylamides, preparation thereof, compositions containing them and use thereof
WO2004006830A3 (en) Use of ccn protein family members for the treatment of disorder associated to an altered calcium and/or sodium flux
WO2005072246A3 (en) Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof
BRPI0313645A2 (en) inhalation compositions with high drug ratios.
WO2005037236A3 (en) Novel heat shock protein 20-related polypeptides and uses therefor
WO2004105705A8 (en) Hair treatment compositions
AU2003219569A1 (en) Antimicrobial peptide, its analogs and antimicrobial composition comprising them
WO2004091542A3 (en) Nitrogen containing integrin targeting compounds
WO2007110772A8 (en) Immunomodulating oligopeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DPEN Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2005714189

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWP Wipo information: published in national office

Ref document number: 2005714189

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007238641

Country of ref document: US

Ref document number: 10599401

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10599401

Country of ref document: US